Conclusion. A high prevalence of ABD -as diagnosed by biochemical markers -was observed in the Background. Adynamic bone disease (ABD) has been described in the current dialysis population to have an European CAPD population. A number of risk factors could be put forward. The aetiology and pathogenesis unexpectedly high prevalence. Moreover, it is clearly more prevalent in CAPD patients, compared to haemo-of this type of renal osteodystrophy remain to be elucidated, but appear, however, to be multifactorial. dialysis patients. Recently we demonstrated that both a low (∏27 U/l ) level of bone alkaline phosphatase Key words: adynamic bone disease; bone alkaline phos-( BAP) as determined by an optimized agarose gel phatase; CAPD; parathyroid hormone electrophoretic technique and a low (∏150 pg/ml ) level of iPTH are good markers of ABD with sensitivities of 78.1% and 80.6% and specificities of 86.4% and 76.2% respectively.
patients, with a clear preponderance in the CAPD 25% of the patients at least one episode of hypercalcaemia population.
was recorded the year prior to inclusion in the study. In
The aetiology and pathogenesis of ABD remain 3 .3% a parathyroidectomy and in 8.4% a previous renal largely unknown. Many authors have shown that transplantation episode was reported. aluminium is no longer the only culprit, since many
The renal diagnoses according to the EDTA code were cases of ABD have been described without any trace chronic glomerulonephritis 24.6%, chronic pyelonephritis of aluminium in bone [3, [5] [6] [7] . Patients with ABD have 19.4%, analgesic nephropathy 2.9%, polycystic kidney disease relatively low iPTH levels [3, [5] [6] [7] [8] [9] [10] . In this respect a 4.3%, diabetic nephropathy 16.4%, renal vascular disease possible role of vitamin-D-induced oversuppression of 10 .1%, other diseases 10.7%, unknown 11.6%. the parathyroid glands has been suggested [11] . In the largest series published so far on the prevalence of Biochemical determinations ABD [3 ] , the effect of vitamin D was, however, not confirmed. Taking into account that ABD apparently In each patient a 10-ml blood sample was collected in the is more prevalent in CAPD than in haemodialysis morning, before administration of the first PD-fluid bag. patients, some authors suggest that the maintenance Blood samples were taken in aluminium-free syringes and centrifuged, approximately 2 h after sampling. The serum of higher calcium levels in these patients induces a was transferred to three dry aluminium-free test tubes (a,b,c) more effective suppression of the parathyroid gland for the determination of (a) iPTH, (b ) total alkaline phos- [3 ] . In the same line of evidence Pei et al. [12] by phatase ( TAP) and isoenzymes by electrophoresis, and multivariant analysis recently demonstrated the intake (c) aluminium. All serum samples were stored immediately of CaCO 3 to be significantly associated with ABD.
at −80°C and forwarded on dry ice to our laboratory.
Other risk factors described for ABD include diaIntact iPTH was measured using the Nichols' IRMA kit betic nephropathy as underlying kidney disease (Nichols Institute, San Juan Capistrano, CA). With this kit [3, [12] [13] [14] , advanced age [3, 9, 14, 15 ] , and shorter time the normal values for patients with normal renal function on dialysis treatment [3 ] .
are between 10 and 65 pg/ml.
The purpose of this study was (i) to evaluate the between the prevalence of ABD in this particular of the sample with a polyclonal antiplacental-intestinal alkalpopulation and previously described possible risk fac-ine phosphatase antibody [16 ] . This pretreatment retards the tors. In order to address these questions 212 CAPD migration of isoenzymes of placental and intestinal origin patients from 11 European centres were examined. and thus allows for better identification and quantification of the bone and liver fractions. If the bone fraction appears to account for more than 50% of the total alkaline phosphatase, sample pretreatment with neuraminidase is applied to
Subjects and methods
allow a complete separation of the liver and bone fractions in order to obtain an accurate determination of the bone Patients isoenzyme. Quantification of the fractions is performed by scanning the gel using a computerized densitometer Ninety-one CAPD-performing centres in 10 European coun-(Appraise, Beckman Instr., Brea, CA). This method has tries were contacted by mail for their participation. We finally been shown to have an intra-assay CV of 2% and an included 212 stable ambulatory patients in 11 centres in six interassay CV of 7% for BAP values within the reference countries (Belgium, 5; The Netherlands, 1; United range [16 ] . The mean value of BAP in subjects with normal Kingdom, 2; France, 1; Germany, 1; Spain, 1 ).
renal function is 40 U/l, the 5th and 95th percentile being 23 At the time a blood sample was taken a questionnaire on and 80 U/l respectively [17] . clinical patient data was completed. The mean age in our Serum aluminium was determined by graphite furnace patient population was 57.1±15.5 years (range 21-89 years), atomic absorption spectrophotometry [18 ] . 50.2% of the patients were male. The mean ages in male and female patients were of 58.3±15.2 years, and 55.9±15.7 years respectively and did not differ statistically (P=0.264).
Statistical analysis
The current medication consisted of calcium-containing phosphate binders in 66.4% of the cases (53.5% CaCO 3 , The results were analysed with SPSS 6.0 for Windows. A logistic regression, using the 'forward stepwise' method 13.8% Ca-acetate), of Al(OH) 3 in 7.8% and of vitamin D analogues in 30.4% (21.2% as 1a-hydroxycholecalciferol and model, was constructed that included both binomial and continuous covariates for the prediction of either low BAP 9.2% as 1,25-dihydroxycholecalciferol ). At the time of sampling, the calcium content of the PD fluid was 1.75 mmol in (i.e. ∏27 U/l ) or low iPTH (i.e. ∏150 pg/ml ). A covariate was considered to be predictive for a low level of the marker 56.7% of the patients versus 1.25 mmol in the remaining 43.3%. The time that a patient had been on his or her current when its estimated coefficient was significantly different from 0 based on the Wald statistic (P<0.05). calcium concentration of PD fluid was registered. For the patients that had been treated by CAPD for longer than 9
For the comparison of the mean of two groups, Student's t-test was used with the appropriate correction for the months (n=130) the mean calcium concentration of the PD fluid per month was calculated as one-ninth of the area inequality of variances. Variables that were not normally distributed, as detected by Kolmogorow-Smirnov goodness under curve of the calcium concentration of the PD fluid of fit test were compared using the Mann-Whitney U test.
(either below or not below the cut-off level) of both markers ( BAP For comparison of more than two groups, Kruskal-Wallis and iPTH) in 204 patients in whom both markers were available ANOVA was used with Mann-Whitney U test for post hoc testing. Categorical data were compared by the chi-square
test. In view of the fact that the sample selection of this cross-sectional study is by random, the results can be analysed either using a cohort or a case-control strategy differential diagnostic thinking where the exposure to a risk factor is known, than odds ratios. These relative risks were calculated as the ratio of 2 prevalence rates, namely the n, absolute numbers of patients. prevalence of the event in the cohort that was exposed to the risk factor and the prevalence rate in the cohort that was not exposed. The confidence interval of the risk estimate was ent covariates: the calcium content of the PD fluid, the constructed after logarithmic transformation [20] .
total time on renal replacement therapy, age, and gender of the patient. The following factors did not possess a significant predictive value in the diagnosis
Results
of a low BAP level: time on peritoneal dialysis, time on previous haemodialysis, duration of former functioning renal transplant, intake of Al(OH ) 3 , intake of The overall prevalence of ABD as diagnosed by a low (∏27 U/l ) level of BAP in European CAPD patients calcium-containing phosphate binders, intake of vitamin D analogues, simultaneous intake of calciumis 42.9%. A comparable prevalence of 43.3% is observed by using a low level of iPTH (∏150 pg/ml ) containing phosphate binders and vitamin D analogues, serum aluminium level, number of episodes of as marker. As is also shown in Figure 1 , these prevalences differ substantially from centre to centre. hypercalcaemia, centre, status postparathyroidectomy, diabetic nephropathy. Further analysis of the four Moreover, it is clear from this Figure that patients with a low level of BAP not always have a low level predictive covariates showed that the prevalence of a low BAP level is significantly (P=0.0002) higher in of iPTH and vice versa. The prevalences of concordant and discordant patients for the two markers are shown the patient group dialysed with a high ( 1.75 mmol ) calcium content of the PD fluid: 53.8% versus 46.2% in Table 1 .
For the prediction of a low BAP level, logistic in the low calcium group. Also the proportion of patients with a low level of BAP was significantly regression analysis identified four significant independ- High prevalence of adynamic bone disease in the European CAPD population 2147 (P=0.008) higher (51.8%) in male patients than in Exploring the patients in whom a low level of BAP was not accompanied by a low iPTH level and vice women ( 33.6%). The mean total time on renal replacement therapy is significantly (P=0.02) shorter in the versa, we observed that in 'low BAP-high iPTH' patients a wide range of high iPTH level was reached patients with a low level of BAP, i.e. 18.7±16.3 months vs 38.6±52.2 months. Patients with low BAP levels (up to 1400 pg/ml ). Also in 'low iPTH, high BAP' patients BAP levels up to 160 U/l were measured. The are significantly older: 61.8±13.8 vs 54.0±15.7 years (P=0.001). Relative risks for a low BAP level were factors shown to be predictive for either a low level of BAP or iPTH were found not to be associated significcalculated for high calcium content of PD fluid, male gender, age Á60 years, and a time on renal replacement antly with either of the discordant groups.
Despite the fact that the median serum aluminium therapy below 30 months (both cut-offs were shown to have the highest likelihood ratio in the finding of a level was only 5 mg/l (range 1-202), and that only 11 (5.1%) patients had a serum level of Á30 mg/l, which low level of BAP). These relative risks and their 95% confidence intervals are shown in Figure 2 .
is considered to be an index of potential aluminium toxicity [21] , it was demonstrated, by Kruskal-Wallis For the prediction of a level of iPTH ∏150 pg/ml logistic regression identified two independent covari-ANOVA, that the serum aluminium levels significantly differed between the four patient groups as defined by ates: the age of the patients and the calcium content of the PD fluid. Neither total time of renal replacement the con-or discordance of their two markers. By
Mann-Whitney U post hoc testing, it could be demontherapy, nor the gender of the patient, nor all the other variables studied in the analysis of BAP ∏27 U/l strated that the 'high BAP, low iPTH' group of patients had higher serum aluminium levels than any other of possessed any significant predictive value. The effect of a high calcium content of the PD fluid on the higher the three groups considered. prevalence of a low level of iPTH was at the limit of significance by x2 testing (P=0.05). Mean age of low Discussion iPTH patients was significantly (P=0.004) higher ( 60.5±13.6 years) than that of high iPTH patients ( 54.5±16.4 years). Relative risks and their 95% con-In view of the small modification by post-translational glycosylation of the tissue unspecific alkaline phosphatfidence intervals for both factors are shown in Figure 2 .
When analysing the subpopulation of the patients ase, which is of liver, bone, and kidney origin, the electrophoretic separation of its isoenzymes requires longer than 9 months on CAPD treatment, the mean calcium concentration of the PD fluid per month was additional procedures to obtain their accurate separation and quantification. By pretreatment of the serum shown also by logistic regression analysis to be a significant risk factor both for a low BAP and low with polyclonal antiplacental-intestinal antibodies before its application on agarose gel we succeeded in iPTH level. Mean calcium concentration of PD fluid per month was shown to be significantly (P=0.01) developing an accurate and reproducible methodology [16 ] . This method was also shown to be equally higher in patients with either BAP∏27 U/l or iPTH∏150 pg/ml. effective in the lower range of BAP; in contrast to Relative risk (and 95% CI) for low level of BAP (∏27 U/l ) or iPTH (∏150 pg/ml ) as calculated for the covariates that were identified by logistic regression analysis.
M. M. Couttenye et al. 2148
determination by means of anti-BAP monoclonals our was not confirmed in our study; here the relative low number of diabetics (n=23), displayed a prevalence of method is not prone to cross-reactivity with the liver isoenzyme [22] . a low level of BAP and iPTH comparable to the overall prevalence (data not shown). Also suppression of bone Recently we demonstrated both BAP ∏27 U/l, as determined by our improved agarose electrophoretic turnover has been described in patients returning into dialysis after transplantation and in parathyroidectomtechnique and iPTH ∏150 pg/ml to be good biochemical markers of ABD as indicated by their sensitivity ized patients. In the present study, none of these risk factors reached a significant relationship with the presof 78.1 and 80.6% and specificity of 86.4 and 76.2% respectively [2] . These diagnostic indices were assessed ence of a low level of either BAP or iPTH. It should be noted, however, that the number of this type of in a multicentre haemodialysis population including patients from outside Europe and patients showing patients was low. On the other hand, older age, which was also described earlier [3, 9, 14 ] to be associated with aluminium-related bone disease. The population under study here differs from the previous one in three the occurrence of ABD, was also in our study a risk factor for the prevalence of low levels of BAP and respects. First, aluminium exposure appeared to be very limited. Only 7.8% of the patients included were iPTH.
The strikingly higher prevalence of ABD in CAPD taking aluminium-containing phosphate binders, and both the mean serum aluminium level, and the number vs haemodialysis patients as shown both by Sherrard et al. [3] and Torres et al. [4 ] has led to the hypothesis of patients reaching the potentially toxic level of 30 mg/l [21 ] were low.
that CAPD is a risk factor for ABD through the exposure of the patient to a higher calcium load As we could show in our previous paper [2 ] , however, aluminium overload decreases the diagnostic per-resulting in oversuppression of the parathyroid glands [3] . In the same line of evidence Pei et al. [12] and formance of low BAP. Indeed, aluminium overload may lead to false negative results of BAP with respect Hercz et al. [7 ] point towards the increasing prevalence of ABD since the previously widespread used Al(OH ) 3 to the diagnosis of ABD. Hence the lack of exposure to aluminium in the present study will reasonably was replaced by calcium-containing phosphate binders and thus higher oral calcium loads are administered increase the sensitivity of BAP. Second, as was recently shown by Torres et al. [4 ] , the bone response to PTH to the patients. Also, oversuppression of the parathyroid glands with vitamin D analogues has been is similar in CAPD and haemodialysis, and thus the value of PTH as a marker of a bone disease can be implicated in the development of ABD [11 ] . In our study, however, no significant relationship between the expected to be comparable. Third, taking into account Torres' data on the prevalence of ABD in CAPD, prevalence of low levels of either BAP or iPTH and the intake of calcium-containing phosphate binders or which is diagnosed by bone biopsies is 48%, and applying Bayes' theorem, it can be calculated that both vitamin D analogues was apparent. The data collected by our questionnaire, however, did not allow for exact for BAP and PTH the positive predictive value will be even higher than the figures published in our previous calculations of cumulative doses of medications. We could only correlate the presence of a low level of report, being 85 and 78% for a prevalence of ABD of 35%; a value based on Sherrard's data [3 ] .
either marker with the fact of a patient was 'on' or 'off ' a medication at the time of blood sampling. On Using low BAP as well as low iPTH we found in the present study a prevalence of ABD of ±43% in the other hand, a high calcium content (1.75 mmol/l ) of the PD fluid, which is also an indicator of the 212 European CAPD patients. This prevalence is considerably lower than the 60% diagnosed histomorpho-calcium load administered to the patients, was strongly predictive of the presence of a low level of BAP. The metrically by Sherrard et al. [3] in a North-American CAPD population (n=142). In this study, however, it high calcium content of the PD fluid was also predictive for the presence of a low level of iPTH but less than is difficult to eliminate aluminium as a contributing factor to this high prevalence, since only 49 of the 128 for low BAP. Since most nephrologists nowadays are well aware of the risk of ABD in patients with low patients with ABD had no measurable bone surface aluminium. Meanwhile it has become clear that ABD iPTH levels, a bias may consist in the sense that the calcium content of the PD fluid is lowered by the can also evolve in the absence of aluminium overload. In the Spanish study of Torres et al. [4 ] the prevalence treating physicians when confronted with decreasing iPTH levels in their patients [23] . This bias, however, of ABD in 32 CAPD patients is closer to ours: 48%. This still rather high prevalence of ABD was present does not interfere with our BAP results, since BAP determination is not yet routinely performed. Indeed, despite a very low bone surface aluminium staining (mean of 0.4%). As already argued before, also in our in the group of patients with iPTH ∏150 pg/ml relatively more (36%) patients were found on a PD fluid patients under study, aluminium will not have been a major cause of ABD.
with low calcium content, than in the patients group with BAP ∏27 U/l (28%). Discarding aluminium as a causative factor in the development of ABD, which was described earlier by
In addition to the current calcium concentration of the PD fluid which is only indicative of the calcium different groups [3, [5] [6] [7] , it appeared recently that other risk factors have to be taken into account also. Diabetic load administered, we also calculated the 'mean calcium concentration of PD fluid per month' for the last patients have been described to be more prone to this type of bone disease than non-diabetics [3, [12] [13] [14] . This 9 months of treatment prior to inclusion in the study, in order to obtain a more accurate estimate of the [29] demonstrated a stimulatory effect of low concentrations of aluminium on osteoblast alkaline phosphatcalcium load administered to the patient. In the subpopulation of patients who had been on CAPD treatment ase activity. Our finding in the CAPD population under study of higher mean serum aluminium levels for more than 9 months (n=130), it was demonstrated that both low BAP and low iPTH patients had signi-(though not frankly toxic) in the group of patients with the 'high BAP, low PTH' profile is in line with ficantly higher calcium exposures, adding evidence to the above-mentioned hypothesis of CAPD patients the idea of a specific effect of aluminium, even at low levels of exposure, on osteoblast activity. being more at risk to oversuppression of the parathyroid glands through exposure to higher calcium Regarding the patients displaying the other type of discordant markers, no definite conclusions can be loads.
The gender of the patients appeared also a determin-drawn. However, due to the different sensitivities and specificities of both markers some discrepant cases are ing factor for the prevalence of a low level of BAP, the male gender being more affected. We are not aware likely. Moreover, one has to take into account that both markers reflect the functional state of two differof literature data confirming this finding. BAP, being a marker of osteoblastic function, might, however, be ent cell types: the osteoblasts and the parathyroid cells.
The exact pathophysiological link between these two systematically higher in female dialysis patients due to their postmenopausal (be it premature or not) state, organs in ABD (is hypoparathyroidism cause or consequence of ABD?) has not been elucidated so far, since the cessation of ovarian function is known to induce a marked increase in bone turnover [24 ] and neither are there prospective data available showing which of these markers responds first to changes of increased levels both of BAP and osteocalcin have been described in postmenopausal osteoporotic treatment such as calcium loading or vitamin D. The findings of Goodman et al.
[30 ] on the development patients with normal renal function [25 ] . Moreover, in their recent bone biopsy study Gerakis et al. [26 ] , also of histologically proven ABD after calcitriol treatment in patients with persistent high iPTH levels is, however, found higher indices of bone formation in women than in men, despite similar levels of iPTH. They also indicative of the discrepant behaviour that may arise between these two organs. Due to the cross-sectional suggest the lack of the antiresorptive effect of oestrogen in postmenopausal women as a possible explanation.
character of our study, it can be argued that in some patients a change in bone turnover (e.g. due to a recent Patients with BAP ∏27 U/l were significantly shorter on renal replacement therapy. Pei et al. [12 ] change of medication) may be already apparent in one marker but not yet in the other. Also our different also found in their multivariant analysis of risk factors for the different types of renal osteodystrophy a signi-results regarding risk factors for either low BAP or low PTH are in agreement with this line of thought. ficantly shorter duration of dialysis in ABD patients. In the paper describing the first cases with non-However, whereas many reasons can be put forward trying to explain the discrepant cases, no data are aluminium-associated ABD Morinière et al. [5] also described shorter time on dialysis of the ABD patients. available regarding the exact value of these findings in the diagnosis of ABD. Also in our previous study on The reason(s) for this phenomenon remain(s) unclear, though the observation of Torres et al. [4 ] that the the evaluation of these markers the number of discrepant profiles encountered were too low to allow for bone response to PTH in renal failure increases after dialysis ( haemo-or peritoneal ) is initiated might offer significant conclusions.
The value of either marker (BAP or iPTH) by itself an explanation: the dialysis treatment might remove toxins responsible for the impaired bone response is well defined. Despite the fact that these markers do not reflect the gold standard for 100%, they may to PTH.
Finally, despite the fact that both a low level of provide us with a good estimate of the prevalence of ABD. In this study, this prevalence was shown to be BAP ∏27 U/l and iPTH ∏150 pg/ml by themselves have good diagnostic performances in the detection of relatively high, confirming earlier biopsy-based data in a smaller but, with regard to the low level of aluminium ABD we were struck by the substantial number of patients with either 'low BAP, high iPTH' or 'high exposure, analogous European CAPD population [4 ] .
Moreover, we could show that besides the known BAP, low iPTH'. Also in our assessment study on the diagnostic value of these markers [2 ] a comparable risk factors of advanced age and shorter time on dialysis, male gender also appears to be a significant percentage of discrepant cases (25.6% in total ) was encountered. In case of the 'high BAP, low PTH' a risk factor for this type of renal osteodystrophy, as well as a high calcium load administered through the significant association could be demonstrated between this profile and the histological and/or chemical evid-dialysate. ence of aluminium overload (unpublished data). The low PTH level in these patients is in accordance with 
